Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Corrigendum to "Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's antiseizure efficacy" [Neuropharmacology 143 (2018) 186-204].

Brandt C, Seja P, Töllner K, Römermann K, Hampel P, Kalesse M, Kipper A, Feit PW, Lykke K, Toft-Bertelsen TL, Paavilainen P, Spoljaric I, Puskarjov M, MacAulay N, Kaila K, Löscher W.

Neuropharmacology. 2018 Dec;143:349-350. doi: 10.1016/j.neuropharm.2018.10.012. Epub 2018 Oct 19. No abstract available.

PMID:
30343990
2.

Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti-seizure efficacy.

Brandt C, Seja P, Töllner K, Römermann K, Hampel P, Kalesse M, Kipper A, Feit PW, Lykke K, Toft-Bertelsen TL, Paavilainen P, Spoljaric I, Puskarjov M, MacAulay N, Kaila K, Löscher W.

Neuropharmacology. 2018 Dec;143:186-204. doi: 10.1016/j.neuropharm.2018.09.025. Epub 2018 Sep 21. Erratum in: Neuropharmacology. 2018 Oct 18;:.

PMID:
30248303
3.

The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy.

Brandt C, Hillmann P, Noack A, Römermann K, Öhler LA, Rageot D, Beaufils F, Melone A, Sele AM, Wymann MP, Fabbro D, Löscher W.

Neuropharmacology. 2018 Sep 15;140:107-120. doi: 10.1016/j.neuropharm.2018.08.002. Epub 2018 Aug 3.

PMID:
30081001
4.
5.

A combination of NMDA and AMPA receptor antagonists retards granule cell dispersion and epileptogenesis in a model of acquired epilepsy.

Schidlitzki A, Twele F, Klee R, Waltl I, Römermann K, Bröer S, Meller S, Gerhauser I, Rankovic V, Li D, Brandt C, Bankstahl M, Töllner K, Löscher W.

Sci Rep. 2017 Sep 22;7(1):12191. doi: 10.1038/s41598-017-12368-6.

6.

Multiple blood-brain barrier transport mechanisms limit bumetanide accumulation, and therapeutic potential, in the mammalian brain.

Römermann K, Fedrowitz M, Hampel P, Kaczmarek E, Töllner K, Erker T, Sweet DH, Löscher W.

Neuropharmacology. 2017 May 1;117:182-194. doi: 10.1016/j.neuropharm.2017.02.006. Epub 2017 Feb 10.

PMID:
28192112
7.

Knockout of P-glycoprotein does not alter antiepileptic drug efficacy in the intrahippocampal kainate model of mesial temporal lobe epilepsy in mice.

Bankstahl M, Klein S, Römermann K, Löscher W.

Neuropharmacology. 2016 Oct;109:183-195. doi: 10.1016/j.neuropharm.2016.06.007. Epub 2016 Jun 7.

PMID:
27288003
8.

Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood-Brain Barrier.

Bauer M, Römermann K, Karch R, Wulkersdorfer B, Stanek J, Philippe C, Maier-Salamon A, Haslacher H, Jungbauer C, Wadsak W, Jäger W, Löscher W, Hacker M, Zeitlinger M, Langer O.

Clin Pharmacol Ther. 2016 Aug;100(2):131-41. doi: 10.1002/cpt.362. Epub 2016 May 9.

9.

Influence of 24-Nor-Ursodeoxycholic Acid on Hepatic Disposition of [(18)F]Ciprofloxacin, a Positron Emission Tomography Study in Mice.

Wanek T, Halilbasic E, Visentin M, Mairinger S, Römermann K, Stieger B, Kuntner C, Müller M, Langer O, Trauner M.

J Pharm Sci. 2016 Jan;105(1):106-12. doi: 10.1016/j.xphs.2015.11.014. Epub 2016 Jan 13.

PMID:
26852845
10.

Network pharmacology for antiepileptogenesis: Tolerability of multitargeted drug combinations in nonepileptic vs. post-status epilepticus mice.

Klee R, Töllner K, Rankovic V, Römermann K, Schidlitzki A, Bankstahl M, Löscher W.

Epilepsy Res. 2015 Dec;118:34-48. doi: 10.1016/j.eplepsyres.2015.11.003. Epub 2015 Nov 10.

PMID:
26600369
11.

Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.

Wanek T, Römermann K, Mairinger S, Stanek J, Sauberer M, Filip T, Traxl A, Kuntner C, Pahnke J, Bauer F, Erker T, Löscher W, Müller M, Langer O.

Mol Pharm. 2015 Sep 8;12(9):3214-25. doi: 10.1021/acs.molpharmaceut.5b00168. Epub 2015 Aug 3.

12.

Structure-activity relationships of bumetanide derivatives: correlation between diuretic activity in dogs and inhibition of the human NKCC2A transporter.

Lykke K, Töllner K, Römermann K, Feit PW, Erker T, MacAulay N, Löscher W.

Br J Pharmacol. 2015 Sep;172(18):4469-4480. doi: 10.1111/bph.13231. Epub 2015 Aug 4.

13.

The AMPA receptor antagonist NBQX exerts anti-seizure but not antiepileptogenic effects in the intrahippocampal kainate mouse model of mesial temporal lobe epilepsy.

Twele F, Bankstahl M, Klein S, Römermann K, Löscher W.

Neuropharmacology. 2015 Aug;95:234-42. doi: 10.1016/j.neuropharm.2015.03.014. Epub 2015 Mar 31.

PMID:
25839899
14.

Pilocarpine-induced convulsive activity is limited by multidrug transporters at the rodent blood-brain barrier.

Römermann K, Bankstahl JP, Löscher W, Bankstahl M.

J Pharmacol Exp Ther. 2015 May;353(2):351-9. doi: 10.1124/jpet.114.221952. Epub 2015 Mar 9.

PMID:
25755207
15.

Approaching complete inhibition of P-glycoprotein at the human blood-brain barrier: an (R)-[11C]verapamil PET study.

Bauer M, Karch R, Zeitlinger M, Philippe C, Römermann K, Stanek J, Maier-Salamon A, Wadsak W, Jäger W, Hacker M, Müller M, Langer O.

J Cereb Blood Flow Metab. 2015 May;35(5):743-6. doi: 10.1038/jcbfm.2015.19. Epub 2015 Feb 11.

16.

The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2).

Römermann K, Helmer R, Löscher W.

Neuropharmacology. 2015 Jun;93:7-14. doi: 10.1016/j.neuropharm.2015.01.015. Epub 2015 Jan 31.

PMID:
25645391
17.

The organic anion transport inhibitor probenecid increases brain concentrations of the NKCC1 inhibitor bumetanide.

Töllner K, Brandt C, Römermann K, Löscher W.

Eur J Pharmacol. 2015 Jan 5;746:167-73. doi: 10.1016/j.ejphar.2014.11.019. Epub 2014 Nov 20.

PMID:
25449033
18.

Drug-induced trafficking of p-glycoprotein in human brain capillary endothelial cells as demonstrated by exposure to mitomycin C.

Noack A, Noack S, Hoffmann A, Maalouf K, Buettner M, Couraud PO, Romero IA, Weksler B, Alms D, Römermann K, Naim HY, Löscher W.

PLoS One. 2014 Feb 4;9(2):e88154. doi: 10.1371/journal.pone.0088154. eCollection 2014.

19.

Marked differences in the effect of antiepileptic and cytostatic drugs on the functionality of P-glycoprotein in human and rat brain capillary endothelial cell lines.

Alms D, Fedrowitz M, Römermann K, Noack A, Löscher W.

Pharm Res. 2014 Jun;31(6):1588-604. doi: 10.1007/s11095-013-1264-4. Epub 2014 Jan 30.

PMID:
24477677
20.

(R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.

Römermann K, Wanek T, Bankstahl M, Bankstahl JP, Fedrowitz M, Müller M, Löscher W, Kuntner C, Langer O.

Nucl Med Biol. 2013 Oct;40(7):873-8. doi: 10.1016/j.nucmedbio.2013.05.012. Epub 2013 Jul 8.

21.

Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro study.

Bankstahl JP, Bankstahl M, Römermann K, Wanek T, Stanek J, Windhorst AD, Fedrowitz M, Erker T, Müller M, Löscher W, Langer O, Kuntner C.

Drug Metab Dispos. 2013 Apr;41(4):754-62. doi: 10.1124/dmd.112.049148. Epub 2013 Jan 10.

PMID:
23305710
22.

The antiepileptic drug mephobarbital is not transported by P-glycoprotein or multidrug resistance protein 1 at the blood-brain barrier: a positron emission tomography study.

Mairinger S, Bankstahl JP, Kuntner C, Römermann K, Bankstahl M, Wanek T, Stanek J, Löscher W, Müller M, Erker T, Langer O.

Epilepsy Res. 2012 Jun;100(1-2):93-103. doi: 10.1016/j.eplepsyres.2012.01.012. Epub 2012 Feb 17.

23.

Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected.

Löscher W, Luna-Tortós C, Römermann K, Fedrowitz M.

Curr Pharm Des. 2011;17(26):2808-28. Review.

PMID:
21827408

Supplemental Content

Loading ...
Support Center